Julie Rowe

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 312 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia

Santosh L. Saraf, Xu Zhang, Tamir Kanias et al. · British Journal of Haematology · 2013 · 116 citations · Full text

Medicine, Hematology, Nephrology +11

Results of a pilot randomised controlled trial to measure the clinical and cost effectiveness of peer support in increasing hope and quality of life in mental health patients discharged from hospital in the UK

Alan Simpson, Chris Flood, Julie Rowe et al. · BMC Psychiatry · 2014 · 104 citations · Full text

Medicine, Pharmacoeconomics, Psychiatry +15

A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma

Devalingam Mahalingam, Julio Peguero, Putao Cen et al. · Cancers · 2019 · 89 citations · Full text

Medicine, Oncology, Pharmacology +16